Colleen A. Lawton, MD
“This is very exciting work and is exactly what we need in prostate cancer,” said Colleen A. Lawton, MD, Vice-Chair of the Medical College of Wisconsin, Milwaukee, and moderator of a press conference where the study by Spratt et al was discussed. “The prognostic measures we use are rough and imperfect, such as [prostate-specific antigen] levels, Gleason score, tumor biopsy, and digital rectal exam. This study is going in the direction we need—understanding the genes involved in the disease and how they interact. I can’t wait to see these data incorporated in our NRG Oncology clinical trials.”
She continued: “Once we have this information, we are going to treat differently. This is tapping into information we did not have before. For example, a low-risk patient under active surveillance might actually be at higher risk genomically, and if so, should receive treatment. An intermediate-risk patient with favorable genomics may only need monitoring.”
Dr. Lawton concluded: “The future looks bright.” ■
Disclosure: Dr. Lawton reported no potential conflicts of interest.
Members of the oncology community have long complained that prostate cancer lags behind breast cancer regarding biomarkers for prognosis and treatment, but the good news is that this gap is narrowing. In the largest study of its kind to date, presented at the 58th Annual Meeting of the American...